[{"id":"6e77a79a-6073-4141-8dd8-cc4d9d61de69","acronym":"","url":"https://clinicaltrials.gov/study/NCT07101900","created_at":"2025-08-09T14:52:51.285Z","updated_at":"2025-08-09T14:52:51.285Z","phase":"Phase 2","brief_title":"68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses","source_id_and_acronym":"NCT07101900","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-08-08"},{"id":"7152824f-51d6-434a-a17c-b34a21be5fde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07037004","created_at":"2025-06-28T13:42:45.741Z","updated_at":"2025-06-28T13:42:45.741Z","phase":"Phase 2","brief_title":"Adding a Probiotic (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery","source_id_and_acronym":"NCT07037004","lead_sponsor":"City of Hope Medical Center","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 05/04/2026","start_date":" 05/04/2026","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2025-06-25"},{"id":"69f52b30-5163-4f46-8cbc-94e44a11b34d","acronym":"NYCRCCL","url":"https://clinicaltrials.gov/study/NCT06949215","created_at":"2025-09-07T01:25:44.584Z","updated_at":"2025-09-07T01:25:44.584Z","phase":"Phase 2","brief_title":"68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision","source_id_and_acronym":"NCT06949215 - NYCRCCL","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-04-29"},{"id":"c5926a3c-11fc-4d8b-a13e-2af41702c630","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866382","created_at":"2021-01-18T19:04:09.999Z","updated_at":"2025-02-25T12:37:16.517Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","source_id_and_acronym":"NCT03866382","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/13/2019","start_date":" 05/13/2019","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-24"},{"id":"39be432b-e1d2-4ded-8099-18c4960548fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06805825","created_at":"2025-02-25T15:15:39.171Z","updated_at":"2025-02-25T15:15:39.171Z","phase":"Phase 1","brief_title":"A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit","source_id_and_acronym":"NCT06805825","lead_sponsor":"Novelty Nobility, Inc.","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NN3201"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 02/03/2025","start_date":" 02/03/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-13"},{"id":"9c0791f2-df06-44ae-99f3-11a3ceff187a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496208","created_at":"2021-01-18T12:02:15.721Z","updated_at":"2025-02-25T15:10:16.692Z","phase":"Phase 1","brief_title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","source_id_and_acronym":"NCT02496208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/22/2015","start_date":" 07/22/2015","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"12b710b2-1109-43fb-8b55-f68f0578591b","acronym":"FIT-001","url":"https://clinicaltrials.gov/study/NCT06026410","created_at":"2023-09-07T16:09:33.674Z","updated_at":"2025-02-25T14:18:15.893Z","phase":"Phase 1","brief_title":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","source_id_and_acronym":"NCT06026410 - FIT-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • HRAS mutation","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Krazati (adagrasib) • darlifarnib (KO-2806)"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-02-12"},{"id":"b94d473a-a828-47ba-9b4c-363678434e70","acronym":"PDIGREE","url":"https://clinicaltrials.gov/study/NCT03793166","created_at":"2021-01-18T18:45:15.236Z","updated_at":"2025-02-25T16:44:31.244Z","phase":"Phase 3","brief_title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","source_id_and_acronym":"NCT03793166 - PDIGREE","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1175","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 09/15/2025","primary_completion_date":" 09/15/2025","study_txt":" Completion: 09/15/2025","study_completion_date":" 09/15/2025","last_update_posted":"2025-02-06"},{"id":"d0aa4f16-7694-44b7-8f9e-f75259b43f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544929","created_at":"2022-09-19T14:56:40.664Z","updated_at":"2025-02-25T16:39:18.617Z","phase":"Phase 1","brief_title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","source_id_and_acronym":"NCT05544929","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 02/20/2026","primary_completion_date":" 02/20/2026","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2025-02-06"},{"id":"42d2a0f4-bf25-41be-9b41-ecad4c959f5d","acronym":"CK-301-101","url":"https://clinicaltrials.gov/study/NCT03212404","created_at":"2021-01-18T15:50:41.447Z","updated_at":"2025-02-25T16:59:32.024Z","phase":"Phase 1","brief_title":"Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers","source_id_and_acronym":"NCT03212404 - CK-301-101","lead_sponsor":"Checkpoint Therapeutics, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Unloxcyt (cosibelimab-ipdl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 11/18/2021","primary_completion_date":" 11/18/2021","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"78abffa2-7b4c-493d-a391-404776dd9c0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01038778","created_at":"2021-01-18T04:04:38.458Z","updated_at":"2025-02-25T16:58:23.955Z","phase":"Phase 1/2","brief_title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT01038778","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 10/29/2009","start_date":" 10/29/2009","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 07/30/2025","study_completion_date":" 07/30/2025","last_update_posted":"2025-02-03"},{"id":"3339f750-4360-456a-b1ee-c276f0735a58","acronym":"","url":"https://clinicaltrials.gov/study/NCT03473730","created_at":"2021-01-18T17:07:06.521Z","updated_at":"2025-02-25T17:29:38.839Z","phase":"Phase 1","brief_title":"Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer","source_id_and_acronym":"NCT03473730","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex (daratumumab)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/29/2018","start_date":" 05/29/2018","primary_txt":" Primary completion: 01/27/2025","primary_completion_date":" 01/27/2025","study_txt":" Completion: 01/27/2025","study_completion_date":" 01/27/2025","last_update_posted":"2025-01-30"},{"id":"9b1c2dc1-3b24-43f9-b184-70bf85aad83b","acronym":"NCI-2018-01648","url":"https://clinicaltrials.gov/study/NCT03682289","created_at":"2021-01-18T18:03:10.694Z","updated_at":"2025-02-25T15:07:56.671Z","phase":"Phase 2","brief_title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","source_id_and_acronym":"NCT03682289 - NCI-2018-01648","lead_sponsor":"Rahul Aggarwal","biomarkers":" MSI • ATM • ARID1A • UGT1A1","pipe":" | ","alterations":" ATM mutation","tags":["MSI • ATM • ARID1A • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-01-28"},{"id":"a3a861f8-7095-4abf-b84e-a9fcbaf9fff3","acronym":"HPGD-ccRCC","url":"https://clinicaltrials.gov/study/NCT06778538","created_at":"2025-02-25T20:17:18.211Z","updated_at":"2025-02-25T20:17:18.211Z","phase":"","brief_title":"Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients","source_id_and_acronym":"NCT06778538 - HPGD-ccRCC","lead_sponsor":"Shang Panfeng","biomarkers":" HPGD","pipe":"","alterations":" ","tags":["HPGD"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/20/2024","study_completion_date":" 11/20/2024","last_update_posted":"2025-01-16"},{"id":"6e09028c-351c-49a3-ae4b-ecc4e168b4c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04267120","created_at":"2021-01-18T20:44:00.448Z","updated_at":"2025-02-25T16:10:00.555Z","phase":"Phase 2","brief_title":"Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)","source_id_and_acronym":"NCT04267120","lead_sponsor":"Washington University School of Medicine","biomarkers":" SDHB • TSC1","pipe":" | ","alterations":" TSC1 deletion","tags":["SDHB • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSC1 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 07/09/2024","primary_completion_date":" 07/09/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-26"},{"id":"bc35390b-c494-4d3a-9a53-91f2d51b7152","acronym":"BrUOG 354","url":"https://clinicaltrials.gov/study/NCT03355976","created_at":"2021-01-18T16:33:58.917Z","updated_at":"2025-02-25T14:37:46.870Z","phase":"Phase 2","brief_title":"BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas","source_id_and_acronym":"NCT03355976 - BrUOG 354","lead_sponsor":"Brown University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 04/30/2018","start_date":" 04/30/2018","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-11-25"},{"id":"7a194544-769d-4908-bc9c-7b8bbff6762b","acronym":"NCI-2012-01247","url":"https://clinicaltrials.gov/study/NCT01684397","created_at":"2023-11-30T22:15:06.234Z","updated_at":"2025-02-25T13:17:55.736Z","phase":"Phase 1/2","brief_title":"Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer","source_id_and_acronym":"NCT01684397 - NCI-2012-01247","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • pazopanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 11/21/2012","start_date":" 11/21/2012","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 05/02/2025","study_completion_date":" 05/02/2025","last_update_posted":"2024-11-06"},{"id":"12b5c747-ed51-4685-a2bb-fc3b4832f8ea","acronym":"CALYPSO","url":"https://clinicaltrials.gov/study/NCT02819596","created_at":"2021-01-18T13:49:36.169Z","updated_at":"2025-02-25T15:07:06.837Z","phase":"Phase 2","brief_title":"MEDI4736 Combinations in Metastatic Renal Cell Carcinoma","source_id_and_acronym":"NCT02819596 - CALYPSO","lead_sponsor":"Queen Mary University of London","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Orpathys (savolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 07/17/2024","primary_completion_date":" 07/17/2024","study_txt":" Completion: 07/17/2024","study_completion_date":" 07/17/2024","last_update_posted":"2024-11-04"},{"id":"3fe2bab7-f015-4c8e-8ce7-bfb349c8c822","acronym":"","url":"https://clinicaltrials.gov/study/NCT04989959","created_at":"2025-03-03T16:24:33.783Z","updated_at":"2025-03-03T16:24:33.783Z","phase":"Phase 1","brief_title":"[18F]PT2385 PET/CT in Patients with Renal Cell Carcinoma","source_id_and_acronym":"NCT04989959","lead_sponsor":"Orhan Kemal Oz","biomarkers":" EPAS1","pipe":"","alterations":" ","tags":["EPAS1"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 08/18/2026","primary_completion_date":" 08/18/2026","study_txt":" Completion: 08/18/2027","study_completion_date":" 08/18/2027","last_update_posted":"2024-11-01"},{"id":"9bde2c1d-6c7b-4625-912b-af143b2d828b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03173560","created_at":"2021-01-18T15:38:52.630Z","updated_at":"2025-02-25T16:06:21.319Z","phase":"Phase 2","brief_title":"Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma","source_id_and_acronym":"NCT03173560","lead_sponsor":"Eisai Inc.","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 343","initiation":"Initiation: 08/17/2017","start_date":" 08/17/2017","primary_txt":" Primary completion: 02/14/2020","primary_completion_date":" 02/14/2020","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-09-19"},{"id":"54e610ca-41de-4129-a9cc-28b0a7d31044","acronym":"SPARC-1","url":"https://clinicaltrials.gov/study/NCT04028245","created_at":"2021-01-29T07:19:33.502Z","updated_at":"2025-02-25T15:43:37.351Z","phase":"Phase 1","brief_title":"A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT04028245 - SPARC-1","lead_sponsor":"Columbia University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • Ilaris (canakinumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 08/15/2019","start_date":" 08/15/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-09"},{"id":"795a3eed-60a1-4800-a0cc-df6e4a85200a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05665361","created_at":"2022-12-27T14:58:35.799Z","updated_at":"2024-07-02T16:34:58.850Z","phase":"Phase 1/2","brief_title":"Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)","source_id_and_acronym":"NCT05665361","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Zumrad (sasanlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/24/2024","start_date":" 04/24/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-05"},{"id":"64411eb8-6d74-4c88-b0b8-fb08d1f38b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT02210117","created_at":"2021-01-18T10:21:09.236Z","updated_at":"2024-07-02T16:34:59.480Z","phase":"Phase 1","brief_title":"Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery","source_id_and_acronym":"NCT02210117","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL17A","pipe":"","alterations":" ","tags":["IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Avastin (bevacizumab) • Yervoy (ipilimumab) • Beianting (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 11/25/2014","start_date":" 11/25/2014","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-06-03"},{"id":"d57a37ea-c795-45b8-8b85-4cd84be6a9c8","acronym":"CYBRID-02","url":"https://clinicaltrials.gov/study/NCT05520099","created_at":"2022-08-29T13:03:18.601Z","updated_at":"2024-07-02T16:35:00.876Z","phase":"","brief_title":"Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform","source_id_and_acronym":"NCT05520099 - CYBRID-02","lead_sponsor":"Elephas","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"],"overall_status":"Recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-27"}]